Agilent Technologies (NYSE:A) Receives Maintains Rating from 888

888 reiterated their maintains rating on shares of Agilent Technologies (NYSE:A – Get Rating) in a research note published on Wednesday morning, Benzinga reports.

A has been the topic of several other reports. TD Cowen reduced their price target on Agilent Technologies from $168.00 to $145.00 and set an outperform rating on the stock in a report on Wednesday. Evercore ISI reduced their price target on Agilent Technologies from $150.00 to $126.00 and set an outperform rating on the stock in a report on Wednesday. Barclays reduced their price target on Agilent Technologies from $140.00 to $135.00 and set an equal weight rating on the stock in a report on Wednesday. SVB Securities dropped their price objective on Agilent Technologies from $170.00 to $145.00 and set an outperform rating on the stock in a research note on Wednesday. Finally, 1-800-FLOWERS.COM reaffirmed a maintains rating on shares of Agilent Technologies in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, Agilent Technologies has an average rating of Moderate Buy and a consensus target price of $151.35.

Agilent Technologies Trading Down 1.2 %

Shares of A stock opened at $119.49 on Wednesday. Agilent Technologies has a 1 year low of $112.52 and a 1 year high of $160.26. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.37 and a quick ratio of 1.53. The stock’s 50 day simple moving average is $133.52 and its two-hundred day simple moving average is $143.94. The company has a market cap of $35.33 billion, a PE ratio of 26.32, a price-to-earnings-growth ratio of 1.79 and a beta of 1.03.

Agilent Technologies (NYSE:A – Get Rating) last issued its quarterly earnings data on Tuesday, May 23rd. The medical research company reported $1.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.01. Agilent Technologies had a return on equity of 30.11% and a net margin of 19.19%. The business had revenue of $1.72 billion for the quarter, compared to the consensus estimate of $1.67 billion. During the same period in the prior year, the business posted $1.13 earnings per share. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. Research analysts predict that Agilent Technologies will post 5.63 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 26th. Investors of record on Monday, July 3rd will be paid a $0.225 dividend. The ex-dividend date is Friday, June 30th. This represents a $0.90 dividend on an annualized basis and a yield of 0.75%. Agilent Technologies’s dividend payout ratio (DPR) is 19.82%.

Hedge Funds Weigh In On Agilent Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Delta Asset Management LLC TN purchased a new position in shares of Agilent Technologies during the 4th quarter valued at about $26,000. Money Concepts Capital Corp purchased a new position in shares of Agilent Technologies during the 4th quarter valued at about $26,000. Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. purchased a new position in shares of Agilent Technologies during the 4th quarter valued at about $27,000. Newbridge Financial Services Group Inc. raised its stake in shares of Agilent Technologies by 217.6% during the 4th quarter. Newbridge Financial Services Group Inc. now owns 216 shares of the medical research company’s stock valued at $32,000 after buying an additional 148 shares during the last quarter. Finally, Ancora Advisors LLC purchased a new position in shares of Agilent Technologies during the 4th quarter valued at about $34,000.

Agilent Technologies Company Profile

(Get Rating)

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.